Year: 2020
Type: review
Abstract: The prevalence of IBD is rising in the Western world. Despite an increasing repertoire of therapeutic targets, a significant proportion of patients suffer chronic morbidity. Studies in mice and humans have highlighted the critical role of regulatory T cells in immune homeostasis, with defects in number and suppressive function of regulatory T cells seen in patients with Crohn's disease. We review the function of regulatory T cells and the pathways by which they exert immune tolerance in the intestinal mucosa. We explore the principles and challenges of manufacturing a cell therapy, and discuss clinical trial evidence to date for their safety and efficacy in human disease, with particular focus on the development of a regulatory T-cell therapy for Crohn's disease.
Source: Gut
Language: English
Topic: Inflammatory Bowel Disease
Subfield: Gastroenterology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Awards: Regulatory T cell therapy for IBD, Inhibition of T-bet-mediated transcriptional elongation as a novel therapeutic target for inflammatory bowel disease., The role of Mediator in T-bet-dependent gene activation and its dysregulation in mucosal inflammatory disease., G4430942700, G5350841751, G6109446177, MICA: Targeted Regulatory T Cell Therapy for Inflammatory Bowel Disease, T-bet as a master regulator of mucosal immunity and inflammatory bowel disease.
OpenAlex ID: W2998028087
